EuMentis Therapeutics is a clinical stage biopharmaceutical company focused on the development of novel circuit-selective drugs to treat high value, high unmet need CNS conditions. EuMentis is planning to file an IND and initiate a Phase 2 trial in schizophrenia with EM-221, a novel PDE10A antagonist, in early 2025. PDE10A inhibitors specifically modulate dopamine signaling in the striatum, and a substantial body of research points to dysregulation of the striatum and associated cortical and basal ganglia networks as an underlying cause of schizophrenia. Based on Phase 1 data to date, EM-221 is expected to be efficacious, better tolerated and much safer than typical and atypical antipsychotics, which have considerable safety and tolerability problems but are the only approved treatments to date. Recent acquisitions of novel drugs for schizophrenia position EM-221 as a high value opportunity.
EM-221 also has potential for Parkinson’s L-dopa induced dyskinesia, and for a number of other conditions as a safer, better tolerated alternative to antipsychotics including Tourette syndrome, adjunctive treatment of depression, agitation in Alzheimer’s, irritability in autism, and bipolar mania.
EuMentis also has a phase 2-ready, uncompetitive, fast-off antagonist of the NMDA receptor, EM-113. A randomized, placebo-controlled clinical trial at a major academic institution found memantine is highly effective in a subpopulation of autism spectrum disorder patients with elevated glutamate in a region of the brain called the anterior cingulate cortex. EuMentis has an open IND, manufactured drug to support a phase 2 study, and an exclusive license to use this biomarker to identify and treat ASD patients with any NMDA antagonist.
For more information, please contact Mike Moyer (mmoyer@lifesciadvisors.com)
EuMentis Therapeutics, Inc. announced today that the Company’s Chief Medical Officer, Randall Marshall, MD, will be presenting at the Tourette Association of America’s TIC-CON24 Research Symposium being held on May 31st in Dallas, Texas.
Download PDFEuMentis Therapeutics, Inc. announced today that the Company’s Chief Medical Officer, Randall Marshall, MD, will be presenting a keynote address at the Autism Parenting Summit being held virtually from May 17th- 20th.
Download PDFEuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury.
Download PDF